NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues.   No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgo's short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination. Reach out to us if you would like to learn more.

NUAgo Therapeutics

Org chart

Teams

Offices